Michael Morgen, PhD, is Director of R&D at Lonza Bend. He has 20 years of experience in pharmaceutical development and has led a number of innovation programmes in oral and non-oral drug delivery. His group currently works primarily in the development of formulation enabling platforms and the associated characterisation techniques for oral bioavailability enhancement and modified release for small molecule drugs. He received his PhD in Physical Chemistry from the University of California at Berkeley (US) in time-resolved spectroscopy and completed post-doctoral work at the University of Texas at Austin (US) in thin film materials for electronics applications. Dr Morgen has co-authored 30 peer-reviewed research articles, six book chapters and is co-inventor of 10 issued patents in drug delivery technology.